Liquidia Corporation
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Liquidia Corporation |
Ticker: | Ticker: LQDA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). The investigation concerns whether Liquidia and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On August 19, 2024, Liquidia issued a press release announcing that “the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)” but “must await the expiration of regulatory exclusivity of a competing product before final approval can be granted.” On this news, the price of Liquidia shares declined by $4.32 per share, or approximately 30.6%, from $14.11 per share on August 18, 2024 to close at $9.79 on August 19, 2024.
On August 19, 2024, Liquidia issued a press release announcing that “the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)” but “must await the expiration of regulatory exclusivity of a competing product before final approval can be granted.” On this news, the price of Liquidia shares declined by $4.32 per share, or approximately 30.6%, from $14.11 per share on August 18, 2024 to close at $9.79 on August 19, 2024.